Genetic and pharmacological blockade of this axis significantly increases the sensitivity to oxaliplatin in vitro and in vivo, providing potential clinical advantage in using PLK1 or CDC7 inhibitor in combination with chemotherapy regimens in treatment of CRC patients. Here, PLK1 is linked to colorectal carcinoma.